ESMOLOL

​

Esmolol is a cardioselective beta-1 adrenergic antagonist (beta-blocker) with a short half-life, making it particularly useful in the context of anesthesia. Its importance in anesthesia can be highlighted by the following factors:

1. Control of hemodynamic response: Esmolol is frequently used to manage the hemodynamic response to endotracheal intubation, surgical stimulation, or extubation, which can cause a transient increase in heart rate and blood pressure. By blocking beta-1 adrenergic receptors, esmolol helps to attenuate these responses and maintain hemodynamic stability during the perioperative period.

2. Management of intraoperative hypertension: Esmolol can be used to treat intraoperative hypertension, particularly in patients with pre-existing hypertension or when sudden increases in blood pressure occur during surgery.

3. Control of heart rate: Esmolol is effective in controlling heart rate during surgery, which is particularly useful in cases where a lower heart rate is desired, such as during vascular, neurosurgical, or ophthalmologic procedures. It may also be used to manage intraoperative arrhythmias, such as atrial fibrillation or supraventricular tachycardia.

4. Myocardial protection: Esmolol has been shown to provide myocardial protection during surgery by reducing myocardial oxygen demand, which can help to prevent myocardial ischemia in patients with coronary artery disease.

5. Short half-life and rapid onset: Esmolol's short half-life (approximately 9 minutes) and rapid onset of action make it ideal for intraoperative use, as its effects can be quickly titrated to the desired level and can be rapidly reversed if needed.

6. Minimal respiratory effects: Unlike non-selective beta-blockers, esmolol's cardioselectivity makes it less likely to cause bronchoconstriction, making it a safer choice for patients with reactive airway diseases such as asthma or chronic obstructive pulmonary disease (COPD).

​​

The mechanism of action of esmolol can be summarized as follows:

​

1. Inhibition of beta-1 adrenergic receptors: Esmolol binds to beta-1 adrenergic receptors on the surface of cardiac myocytes, competing with endogenous catecholamines such as norepinephrine and epinephrine. By blocking these receptors, esmolol inhibits the activation of adenylate cyclase, which is responsible for converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). This leads to a decrease in intracellular cAMP levels.

2. Decreased intracellular cAMP: Lower levels of cAMP reduce the activation of protein kinase A (PKA), a downstream effector in the beta-adrenergic signaling pathway. PKA is responsible for phosphorylating various proteins involved in regulating cardiac contractility, heart rate, and conduction.

3. Reduced heart rate and contractility: By inhibiting PKA, esmolol leads to a decrease in heart rate (negative chronotropic effect) and a decrease in the force of cardiac contractions (negative inotropic effect). This helps to control the heart rate and reduce the myocardial oxygen demand.

4. Prolonged atrioventricular (AV) conduction time: Esmolol also affects the electrical conduction system of the heart by prolonging the AV conduction time, which can be beneficial in treating certain supraventricular arrhythmias.

5. Cardioselectivity: Esmolol has a higher affinity for beta-1 adrenergic receptors compared to beta-2 receptors, which are primarily found in the bronchial and vascular smooth muscle. This selectivity allows esmolol to primarily affect the heart without causing significant bronchoconstriction or peripheral vasoconstriction, making it more suitable for use in patients with reactive airway diseases or peripheral vascular disease.

​

​

                                                                                         Key points about Esmolol

​

• Esmolol is a rapid-onset and short-acting selective beta 1-adrenergic receptor antagonist.

 

• The elimination half-time of esmolol is about 9 minutes, reflecting its rapid hydrolysis in the blood by plasma esterases.

 

• Plasma esterases responsible for the hydrolysis of esmolol are distinct from plasma cholinesterase.

 

• Beta-adrenergic antagonists produce negative inotropic and chronotropic effects.

 

• The rate of spontaneous phase 4 depolarization is decreased.

 

• Glucagon has been described as the drug of choice to treat massive beta-adrenergic antagonist overdose.

 

​​

 

​​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

​​

​​